Metagenomi Therapeutics (MGX) Assets Average (2024 - 2026)

Metagenomi Therapeutics (MGX) has 3 years of Assets Average data on file, last reported at $209.0 million in Q1 2026.

• Assets Average for Q1 2026 came in at $209.0 million, down 32.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $209.0 million (down 32.84% YoY), and the FY2025 annual result was $272.9 million, down 20.85% from the prior year.
• Assets Average eased to $209.0 million in Q1 2026 per MGX's latest filing, from $234.5 million in the prior quarter.
• Over five years, Assets Average peaked at $400.7 million in Q2 2024 and troughed at $209.0 million in Q1 2026.
• A 3-year average of $311.6 million and a median of $311.2 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average slipped 20.22% in 2025, then tumbled 32.84% in 2026.
• A 3-year view of Assets Average shows it stood at $341.5 million in 2024, then tumbled by 31.32% to $234.5 million in 2025, then fell by 10.87% to $209.0 million in 2026.
• Business Quant data shows MGX's Assets Average at $209.0 million in Q1 2026, $234.5 million in Q4 2025, and $260.1 million in Q3 2025.